|
業務類別
|
Biotechnology |
|
業務概覽
|
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO,formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity. |
| 公司地址
| 321 Harrison Avenue, Boston, MA, USA, 02118 |
| 電話號碼
| +1 617 221-9059 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.pyxisoncology.com |
| 員工數量
| 56 |
| Mr. Jitendra Wadhane |
Principal Financial Officer, Chief Accounting Officer and Senior Vice President, Finance |
-- |
03/07/2025 |
| Mr. Thomas Civik |
Director and Interim Chief Executive Officer |
-- |
06/02/2026 |
|
|
| Dr. Jakob Dupont, M.D.,PhD |
Independent Director |
29/04/2025 |
| Dr. Lara S. Sullivan, M.D. |
Director |
06/02/2026 |
| Mr. Thomas Civik |
Director and Interim Chief Executive Officer |
06/02/2026 |
| Mr. Darren S. Cline, M.B.A. |
Independent Director |
29/04/2025 |
| Dr. Rachel Humphrey, M.D. |
Independent Director |
29/04/2025 |
| Dr. Santhosh Palani, C.F.A.,PhD |
Independent Director |
29/04/2025 |
| Dr. Freda C. Lewis-Hall,M.D. |
Independent Director |
29/04/2025 |
| Mr. John L. Flavin |
Chairman of the Board |
29/04/2025 |
| Mr. Michael A. Metzger |
Independent Director |
29/04/2025 |
|
|
|
|
